<i>RYK</i> Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients

• Main Authors: Ricardo D. Gonzalez (Author), George W. Small (Author), Adrian J. Green (Author), Farida S. Akhtari (Author), Tammy M. Havener (Author), Julia C. F. Quintanilha (Author), Amber B. Cipriani (Author), David M. Reif (Author), Howard L. McLeod (Author), Alison A. Motsinger-Reif (Author), Tim Wiltshire (Author)
• Format: Book
• Published: MDPI AG, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Temozolomide (TMZ) chemotherapy is an important tool in the treatment of glioma brain tumors. However, variable patient response and chemo-resistance remain exceptionally challenging. Our previous genome-wide association study (GWAS) identified a suggestively significant association of SNP rs4470517...